<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6365">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651403</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-174-0144</org_study_id>
    <secondary_id>2012-000586-20</secondary_id>
    <nct_id>NCT01651403</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Poland: The Central Register of Clinical Trials</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled study evaluates the efficacy, safety and tolerability of tenofovir
      disoproxil fumarate (TDF) in participants 2 to &lt; 12 years old with chronic Hepatitis B
      infection.  While studies have shown significant virologic response in adults and
      adolescents, the effect in children is not well established.  This study will provide
      valuable data that can help establish the efficacy and safety profiles of TDF in children.
      The study will consist of 72 weeks of blinded randomized treatment, after which participants
      will switch to open-label TDF treatment for an additional 120 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with serum HBV DNA &lt; 400 copies/mL at week 72</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hepatitis B e antigen (HBeAg) seroconversion at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of at least 4% decrease from baseline in bone mineral density of lumbar spine</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in bone mineral density of lumbar spine</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with normal ALT and normalization of ALT</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of proportion of participants with HBV DNA &lt; 400 copies/mL and normal ALT</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic changes from baseline within the HBV polymerase for patients who were viremic (HBV DNA &gt; or equal 400 copies/mL) with confirmed virologic breakthrough</measure>
    <time_frame>Weeks 72, 144, 192 or Early Discontinuation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HBV DNA &lt; 169 copies/mL</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HBsAg loss and seroconversion</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>Tenofovir DF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tenofovir disoproxil fumarate  (tenofovir DF; TDF) for 72 weeks during the blinded randomized treatment, and will switch to open-label TDF treatment for an additional 120 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match TDF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match TDF for 72 weeks during the blinded randomized treatment, and will switch to open-label TDF treatment for an additional 120 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF</intervention_name>
    <description>Participants ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).
Participants &lt; 17 kg and participants ≥ 17 kg who are unable to swallow a tablet will receive oral powder containing 40 mg of TDF once daily.</description>
    <arm_group_label>Tenofovir DF</arm_group_label>
    <arm_group_label>Placebo to match TDF</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match TDF</intervention_name>
    <description>Matching placebo oral tablet / oral powder
Participants ≥ 17 kg will receive one tablet of placebo to match TDF administered orally once daily
Participants &lt; 17 kg and participants ≥ 17 kg who are unable to swallow a tablet will receive placebo to match TDF oral powder once daily</description>
    <arm_group_label>Placebo to match TDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female, 2 to &lt; 12 years of age

          -  Weight ≥ 10kg

          -  Chronic HBV infection ≥ 6 months

          -  HBeAg-positive or HBeAg-negative

          -  HBV Viral Load ≥ 100,000 copies/mL

          -  Alanin aminotransferase (ALT) ≥ 1.5 x the upper limit of the normal range (ULN) at
             screening

          -  Creatinine Clearance ≥ 80 mL/min

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3, hemoglobin ≥ 10g/dL

          -  Negative pregnancy test at screening

          -  No prior tenofovir DF therapy (subjects may have received prior interferon‑alfa
             and/or other oral anti‑HBV nucleoside/nucleotide therapy; subjects must have
             discontinued interferon-alfa therapy ≥ 6 months prior to screening; subjects
             experienced on other anti-HBV nucleoside/nucleotide therapy must have discontinued
             therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo
             arm)

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Decompensated liver disease

          -  Received interferon therapy within 6 months of Screening

          -  Received anti-HBV nucleoside/nucleotide therapy within 16 weeks of Screening

          -  Alpha-fetoprotein levels &gt; 50 ng/mL

          -  Evidence of hepatocellular carcinoma (HCC)

          -  Co-infection with HIV, acute hepatitis A virus (HAV), hepatitis C virus (HCV), or
             hepatitis D virus (HDV)

          -  Chronic liver disease not due to HBV

          -  History of significant renal, cardiovascular, pulmonary, neurological or bone disease

          -  Long term non-steroidal, anti-inflammatory drug therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bittoo Kanwar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Walker</last_name>
    <email>yvonne.walker@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Georgi Stranski Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plodiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Tokuda Hospital&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gandhi Hospital and Medical College</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500-033</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Prasad</state>
        <zip>530 002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital Private Limited</name>
      <address>
        <city>Gujarat</city>
        <zip>395 002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital, Department of Pediatrics</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Severance Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan-si</city>
        <zip>626 770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Infectious Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute - Constantinesco</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grigore Alexandrescu Emergency Clinical Hospital for Children</name>
      <address>
        <city>Bucharest</city>
        <zip>011743</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Infectious Diseases Hospital of Constanta</name>
      <address>
        <city>Constanta</city>
        <zip>900708</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>&quot;Victor Babes&quot; Clinical Hospital of Infectious Diseases and Pneumophtisology</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Bulgaria</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
